Filing Flows › International Stem Cell (ISCO) › Q2 2026
International Stem Cell (ISCO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
International Stem Cell (ISCO) reported revenue of $2.7M for the second quarter 2026 (Q2 2026), +9% from a year earlier and +16% from the quarter before. Operating margin was -1.3%, net loss $71K (2.7% of revenue).
International Stem Cell, Q2 2026: revenue $2.7M (+9% year over year), operating margin -1.3%, net loss $71K, operating cash flow $167K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $2.7M | +16% | +9% |
| Operating profit | −$35K | — | -121% |
| Net earnings | −$71K | — | -155% |
| Operating cash flow | $167K | +38% | — |
| Free cash flow | $160K | +63% | — |
What changed
Revenue was $2.7M in Q2 2026, up 9% year over year and up 16% from the previous quarter. Biomedical Market was the largest line at 94% of revenue. Biomedical Market added $221K year over year (up 10%), 97% of the total change.
Operating costs exceeded revenue by $35K, an operating margin of -1.3%. Total costs grew 19% against revenue growth of 9%. The fastest-growing cost line was Cost of revenue (+31%). The quarter ended with a net loss of $71K, narrower than the previous quarter's $220K loss. Net interest and other expense of $36K was the main reason.
Operating cash flow was $167K. Non-cash charges added back $28K of depreciation and amortization and $59K of share-based compensation. Working capital and other items added $151K. Capital expenditures of $7K left free cash flow of $160K.
Questions
What was International Stem Cell's revenue in the second quarter 2026?
International Stem Cell (ISCO) reported revenue of $2.7M for the second quarter 2026 (Q2 2026), +9% from a year earlier and +16% from the quarter before.
Was International Stem Cell profitable in the second quarter 2026?
Operating loss was $35K (-1.3% of revenue) and net loss $71K.